Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
CFRX

ContraFect

$1.90

(0.00%)

, MTNB

Matinas BioPharma

$0.41

0.0024 (0.59%)

08:25
08/22/18
08/22
08:25
08/22/18
08:25
Conference/Events
FDA to hold a public workshop »

The FDA holds a two day…

CFRX

ContraFect

$1.90

(0.00%)

MTNB

Matinas BioPharma

$0.41

0.0024 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

CFRX

ContraFect

$1.90

(0.00%)

, MTNB

Matinas BioPharma

$0.41

0.0024 (0.59%)

04:55
08/22/18
08/22
04:55
08/22/18
04:55
Conference/Events
FDA to hold a public workshop »

The FDA holds a two day…

CFRX

ContraFect

$1.90

(0.00%)

MTNB

Matinas BioPharma

$0.41

0.0024 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

CFRX

ContraFect

, MTNB

Matinas BioPharma

16:34
08/21/18
08/21
16:34
08/21/18
16:34
Conference/Events
FDA to hold a public workshop »

The FDA holds a two day…

CFRX

ContraFect

MTNB

Matinas BioPharma

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

CFRX

ContraFect

$1.90

-0.06 (-3.06%)

, MTNB

Matinas BioPharma

$0.41

0.045 (12.50%)

08:20
08/21/18
08/21
08:20
08/21/18
08:20
Conference/Events
FDA to hold a public workshop »

The FDA holds a two day…

CFRX

ContraFect

$1.90

-0.06 (-3.06%)

MTNB

Matinas BioPharma

$0.41

0.045 (12.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

Over a month ago
MTNB

Matinas BioPharma

$0.41

0.0075 (1.85%)

09:18
07/09/18
07/09
09:18
07/09/18
09:18
Hot Stocks
NIH, Matinas BioPharma announce research collaboration for HIV therapy »

Matinas BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
MTNB

Matinas BioPharma

$0.55

-0.0816 (-12.92%)

08:05
06/19/18
06/19
08:05
06/19/18
08:05
Syndicate
Matinas BioPharma raises $8M in a public offering »

Matinas BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTNB

Matinas BioPharma

$1.09

0.04 (3.81%)

17:02
03/16/18
03/16
17:02
03/16/18
17:02
Hot Stocks
Matinas BioPharma names Jerome Jabbour CEO »

Matinas BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

MTNB

Matinas BioPharma

$1.21

-0.01 (-0.82%)

07:36
01/08/18
01/08
07:36
01/08/18
07:36
Hot Stocks
Matinas achieves statistical endpoint for success in MAT2203 Phase 2a study »

Matinas BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTNB

Matinas BioPharma

$1.14

-0.01 (-0.87%)

04:55
10/25/17
10/25
04:55
10/25/17
04:55
Conference/Events
Matinas BioPharma management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

MTNB

Matinas BioPharma

$1.15

-0.08 (-6.50%)

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
Matinas BioPharma management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.